Biogen: presents new data on felzartamab

(CercleFinance.com) - Biogen announced today that the company will present a variety of new data from its felzartamab clinical development program at Kidney Week 2024, Nephrology's annual meeting to be held October 23-27 in San Diego, California.


Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated diseases.

' Our team is focused on the rapid advancement of felzartamab in several Phase 3 studies, and this meeting is an excellent platform to highlight the clinical profile of felzartamab in IgAN', said Travis Murdoch, Head of HI-Bio at Biogen.

Biogen's presentations include an oral presentation highlighting the conclusive data from the IGNAZ Phase 2 study of felzartamab for IgA nephropathy (IgAN). A second oral presentation will review exploratory analyses assessing the impact of felzartamab on key biomarkers associated with IgAN.

Copyright (c) 2024 CercleFinance.com. All rights reserved.